Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

BACKGROUND: Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer’s disease (AD). METHODS: Two of four phase 3, multicenter, randomized, double-blind, placebo-controlled, 18-month trials were conducted g...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Alzheimers Res Ther
Glavni autori: Vandenberghe, Rik, Rinne, Juha O., Boada, Mercè, Katayama, Sadao, Scheltens, Philip, Vellas, Bruno, Tuchman, Michael, Gass, Achim, Fiebach, Jochen B., Hill, Derek, Lobello, Kasia, Li, David, McRae, Tom, Lucas, Prisca, Evans, Iona, Booth, Kevin, Luscan, Gerald, Wyman, Bradley T., Hua, Lisa, Yang, Lingfeng, Brashear, H. Robert, Black, Ronald S.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4866415/
https://ncbi.nlm.nih.gov/pubmed/27176461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-016-0189-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items